Efficacy of adalimumab as second-line therapy in a pediatric cohort of Crohn’s disease patients who failed infliximab therapy: the Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition experience

MLA

Giovanna Zuin, et al. “Efficacy of Adalimumab as Second-Line Therapy in a Pediatric Cohort of Crohn’s Disease Patients Who Failed Infliximab Therapy: The Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition Experience.” Biologics : Targets & Therapy, vol. 13, Jan. 2019, pp. 13–21. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....ae3e036c24e71f4ebeae9b5a49196447&authtype=sso&custid=ns315887.

APA

Giovanna Zuin, Erasmo Miele, Marina Aloi, Paolo Lionetti, Claudio Romano, Monia Gennari, Salvatore Accomando, Alberto Ravelli, Stefano Martelossi, Patrizia Alvisi, Costantino De Giacomo, Lucio Balzani, Graziella Guariso, Serena Arrigo, Salvatore Cucchiara, & Daniela Knafelz. (2019). Efficacy of adalimumab as second-line therapy in a pediatric cohort of Crohn’s disease patients who failed infliximab therapy: the Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition experience. Biologics : Targets & Therapy, 13, 13–21.

Chicago

Giovanna Zuin, Erasmo Miele, Marina Aloi, Paolo Lionetti, Claudio Romano, Monia Gennari, Salvatore Accomando, et al. 2019. “Efficacy of Adalimumab as Second-Line Therapy in a Pediatric Cohort of Crohn’s Disease Patients Who Failed Infliximab Therapy: The Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition Experience.” Biologics : Targets & Therapy 13 (January): 13–21. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....ae3e036c24e71f4ebeae9b5a49196447&authtype=sso&custid=ns315887.